Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) - Digest Version -
Tóm tắt
Từ khóa
Tài liệu tham khảo
1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
2. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851.
3. The Antiarrhythmic Drugs Guideline Committee. The Guidelines for the use of antiarrhythmic drugs: Commentary on the CD-ROM version of the Guidelines and concept of the Sicilian Gambit. Tokyo: Lifemedicom Co., ltd. 2000 (in Japanese).
4. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (1999-2000 JCS Joint Working Groups Report). Guidelines for Pharmacotherapy of Atrial Fibrillation. Jpn Circ J 2001; 65(Suppl V): 931-978 (in Japanese).
5. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2001; 104: 2118-2150.
6. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2006; 114: 700-752.
7. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995; 155: 469-473.
12. Research Group for Antiarrhythmic Drug Therapy. Atrial fibrillation and thromboembolism: A multicenter cooperative study. J Cardiol 1998; 31: 227-238 (in Japanese).
13. Tomita F, Kohya T, Sakurai M, Kaji T, Yokoshiki H, Sato M, et al; for the Hokkaido Atrial Fibrillation Study Group. Prevalence and clinical characteristics of patients with atrial fibrillation. Analysis of 20,000 cases in Japan. Jpn Circ J 2000; 64: 653-658.
14. Lévy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study. Circulation 1999; 99: 3028-3035.
18. Fujishima M. Heart disease: Risk factor of cerebral vessel disease. The Journal of Board Certified Member of the Japanese Circulation Society 1998; 6: 19-26 (in Japanese).
21. Jaïs P, Haïssaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95: 572-576.
22. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.
27. Pappone C, Rosanio S, Oreto G, Tocchi M, Gugliotta F, Vicedomini G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000; 102: 2619-2628.
28. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
29. Tanabe Y, Chinushi M, Taneda K, Fujita S, Kasai H, Yamaura M, et al. Recovery of the right atrial effective refractory period after cardioversion of chronic atrial fibrillation. Am J Cardiol 1999; 84: 1261-1264.
30. Sato T, Mitamura H, Kurita Y, Takeshita A, Shinagawa K, Miyoshi S, et al. Recovery of electrophysiological parameters after conversion of atrial fibrillation. Int J Cardiol 2001; 79: 183-189.
33. Mary-Rabine L, Albert A, Pham TD, Hordof A, Fenoglio JJ Jr, Malm JR, et al. The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 1983; 52: 188-199.
35. Kanagaratnam P, Dupont E, Rothery S, Coppen S, Severs NJ, Peters NS. Human atrial conduction and arrhythmogenesis correlates with conformational exposure of specific epitopes on the connexin40 carboxyl tail. J Mol Cell Cardiol 2006; 40: 675-687.
39. Yamashita T, Murakawa Y, Hayami N, Fukui E, Kasaoka Y, Inoue M, et al. Short-term effects of rapid pacing on mRNA level of voltage-dependent K+ channels in rat atrium: Electrical remodeling in paroxysmal atrial tachycardia. Circulation 2000; 101: 2007-2014.
40. Coumel P. Neural aspects of paroxysmal atrial fibrillation. <i>In</i>: Falk RH, Podrid PJ, editors. Atrial fibrillation: Mechanisms and management. New York: Raven Press, 1992; 109-125.
46. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301: 1080-1085.
48. Allessie MA, Lammers WJEP, Bonke FIM, Hollen J. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. <i>In</i>: Zipes DP, Jalife J, editors. Cardiac electrophysiology and arrhythmias. Orlando, Grune & Stratton, 1985; 265-275.
49. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100: 1879-1886.
52. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: Insights into the mechanism of its maintenance. Circulation 1997; 95: 511-521.
53. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: A new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977; 41: 9-18.
54. Dillon SM, Allessie MA, Ursell PC, Wit AL. Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarcts. Circ Res 1988; 63: 182-206.
55. Pertsov AM, Davidenko JM, Salomonsz R, Baxter WT, Jalife J. Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. Circ Res 1993; 72: 631-650.
56. Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62: 395-410.
57. Nattel S, Li D. Ionic remodeling in the heart: Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000; 87: 440-447.
63. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2006; 114: e257-e354.
64. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, et al. New-onset atrial fibrillation: Sex differences in presentation, treatment, and outcome. Circulation 2001; 103: 2365-2370.
65. Kato T, Yamashita T, Sagara K, Iinuma H, Fu LT. Progressive nature of paroxysmal atrial fibrillation: Observations from a 14-year follow-up study. Circ J 2004; 68: 568-572.
67. Van Gelder IC, Crijns HJ, Tieleman RG, Brügemann J, De Kam PJ, Gosselink AT, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156: 2585-2592.
68. Camm AJ, Savelieva I, Baharati S, Lindsay BD, Nattel S, Shinagawa K, et al. Atrial tachycardia, flutter, and fibrillation. <i>In</i>; Electrophysiological disorders of the heart. Sakesena S, Camm AJ, editors. Philadelphia: Elsevier, Churchill Livingstone, 2005; 283-363.
69. J-RHYTHM Study.
70. McKenna WJ, Alfonso A. Arrhythmias in the cardiomyopathies and mitral valve prolapse. <i>In</i>: Zipes D, Rowlands D, editors. Progress in cardiology. Philadelphia: Lea & Febiger, 1988; 59-75.
71. Pollick C. Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982; 307: 997-999.
72. Hamada M, Sigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, et al. Class Ia antiarrhythmic drug cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520-1524.
74. Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K, et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 2000; 21: 327-333.
78. Kopecky SL, Gersh BJ, McGoon MD, Chu CP, Ilstrup DM, Chesebro JH, et al. Lone atrial fibrillation in elderly persons: A marker for cardiovascular risk. Arch Intern Med 1999; 159: 1118-1122.
79. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669-674.
80. Odakura H, Ito M. Lone atrial fibrillation. <i>In</i>: Hayakawa H, Kasanuki H, editors. Atrial fibrillation, flutter, and tachycardia. Tokyo: Igaku-Shoin Ltd., 1999; 288-292 (in Japanese).
81. Frost L. Lone atrial fibrillation: Good, bad, or ugly? Circulation 2007; 115: 3040-3041.
83. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
84. Hagens VE, Ranchor AV, Van Sonderen ELP, Bosker HA, Kingma T, Van Gelder C. Quality of life in persistent atrial fibrillation in the RACE study. Circulation 2002; 106: II-634.
86. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030.
92. Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006; 70: 651-656.
93. Yamaguchi T for Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial. Stroke 2000; 31: 817-821.
95. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation: A statement for healthcare professionals. From the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93: 1262-1277.
96. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention. Ann Intern Med 1999; 131: 688-695.
97. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: Consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J 1982; 104: 617-621.
99. Mehta D, Baruch L. Thromboembolism following cardioversion of "common" atrial flutter: Risk factors and limitations of transesophageal echocardiography. Chest 1996; 110: 1001-1003.
100. Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter: A prospective study using transesophageal echocardiography. Circulation 1997; 95: 962-966.
104. Morimoto Y, Niwa H, Yoneda T, Kimura K, Yasaka M, Minematsu K. Hemostatic management of tooth extraction in patients undergoing antithrombotic therapy. J Jpn Stomatol Soc 2004; 53: 74-80 (in Japanese).
105. Makiura N, Yasaka M, Minematsu K. Management of hemorrhagic complications at dental extraction in patients treated with warfarin. Jpn J Stroke 2005; 27: 424-427 (in Japanese).
106. Morimoto Y, Niwa H, Yoneda T, Shimabukuro Y, Kitamura M, Murakami S, et al. Hemostatic management of dental treatments in the patients undergoing antithrombotic therapy. Journal of the Japanese Association for Dental Science: JJDS 2006; 25: 93-98 (in Japanese).
107. Ardekian L, Gaspar R, Peled M, Brener B, Laufer D. Does low-dose aspirin therapy complicate oral surgical procedures? J Am Dent Assoc 2000; 131: 331-335.
108. Katz J, Feldman MA, Bass EB, Lubomski LH, Tielsch JM, Petty BG, et al; Study of Medical Testing for Cataract Surgery Team. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 2003; 110: 1784-1788.
109. Yasaka M, Okada Y, Enaida H, Takahashi S, Yamaguchi T. A questionnaire survey on antithrombotic therapy during cataract surgery. Jpn Med J 2008; 4382: 74-75 (in Japanese).
110. Ogoshi K, Kaneko E, Tada M, Mine T, Yoshino J, Yahagi N, et al. The management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastroenterol Endosc 2005; 47: 2691-2695 (in Japanese).
111. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2002-2003 JCS Joint Working Groups Report). Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease. Circ J 2004; 68(Suppl IV): 1153-1219 (in Japanese).
112. Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003; 89: 278-283.
114. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115: 455-459.
115. Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, García RC, et al. Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion. Mayo Clin Proc 2007; 82: 82-92.
119. Aosaki M, Iwade K, Echizen H. V-1: Use during pregnancy (contraindications). <i>In</i>: Aosaki M, Iwade K, Echizen H, editors. Warfarin-Proper use information version 3. Tokyo: Eisai Co., Ltd., 2007; 107-109 (in Japanese).
120. Uetsuka Y, Higashidate N, Aosaki M, Matsumura K, Fukui T, Iwade K, et al. Fifteen-year experience with 24 pregnancies associated with prosthetic valve replacements. J Cardiol 1990; 20: 929-935 (in Japanese).
124. Lundström T, Rydén L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86-90.
125. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation: Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 1997; 18: 649-654.
126. Enjoji Y, Sugi K, Kasao M, Ikeda T, Noro M, Sakata T, et al. The usefulness of aprindine for the defibrillation of paroxysmal atrial fibrillation resistant to DC shock. Kokyu To Junkan 1996; 44: 1287-1291 (in Japanese).
127. Suttorp MJ, Kingma JH, Jessurun ER, Lie-A-Huen L, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722-1727.
128. Capucci A, Boriani G, Rubino I, Della Casa S, Sanguinetti M, Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting resent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994; 43: 305-313.
131. Azpitarte J, Alvarez M, Baún O, García R, Moreno E, Martín F, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997; 18: 1649-1654.
132. Okishige K, Fukunami M, Kumagai K, Atarashi H, Inoue H; Pilsicainide Suppression Trial for Persistent Atrial Fibrillation II Investigators. Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: Pilsicainide suppression trial for persistent atrial fibrillation II. Circ J 2006; 70: 657-661.
134. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2002-2003 JCS Joint Working Groups Report). Guidelines for pharmacologic treatment of arrhythmias. Circ J 2004; 68(Suppl IV): 981-1053 (in Japanese).
135. The Antiarrhythmic Drugs Guideline Committee of the Japanese Society of Electrocardiology. Prospects for preparation of the guidelines for the use of antiarrhythmic drugs according to the Sicilian Gambit. Electrocardiography 1997; 17: 191-197 (in Japanese).
138. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
140. Matsumoto K, Sumita S, Ishikawa T, Matsushita K, Kobayashi T, Ohkusu Y, et al. Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: A case report. J Cardiol 2003; 42: 227-234 (in Japanese).
143. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.
145. Pedersen OD, Bagger H, Køber L, Trop-Pedersen C; on behalf of the TRACE Study Group. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
149. Watanabe E, Arakawa T, Uchiyama T, Kani A, Kato K, Kodama I, et al. Prevention of paroxysmal atrial fibrillation by class I antiarrhythmic drugs based on diurnal event variation. Electrocardiology 2003; 23: 45-52 (in Japanese).
171. Cummings JE, Schweikert RA, Saliba WI, Burkhardt JD, Kilikaslan F, Saad E, et al. Brief communication: Atrialesophageal fistulas after radiofrequency ablation. Ann Intern Med 2006; 144: 572-574.
173. Brignole M, Menozzi C, Gianfranchi L, Musso G, Mureddu R, Bottoni N, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: A randomized, controlled study. Circulation 1998; 98: 953-960.